IRIS
PATRIARCA, Francesca
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 11.229
EU - Europa 2.845
AS - Asia 1.164
Continente sconosciuto - Info sul continente non disponibili 14
AF - Africa 10
OC - Oceania 5
SA - Sud America 5
Totale 15.272
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 11.175
UA - Ucraina 1.054
CN - Cina 492
SG - Singapore 446
DE - Germania 418
IT - Italia 363
FI - Finlandia 319
SE - Svezia 227
IE - Irlanda 198
RU - Federazione Russa 149
TR - Turchia 78
VN - Vietnam 69
CA - Canada 53
GB - Regno Unito 53
IN - India 35
BE - Belgio 20
IR - Iran 19
EU - Europa 14
FR - Francia 10
NL - Olanda 10
JP - Giappone 8
TG - Togo 8
CZ - Repubblica Ceca 7
AU - Australia 5
HK - Hong Kong 5
RO - Romania 4
RS - Serbia 4
KR - Corea 3
BR - Brasile 2
CH - Svizzera 2
IL - Israele 2
SA - Arabia Saudita 2
TW - Taiwan 2
AR - Argentina 1
AT - Austria 1
BG - Bulgaria 1
CO - Colombia 1
DK - Danimarca 1
EG - Egitto 1
ID - Indonesia 1
JO - Giordania 1
KZ - Kazakistan 1
LT - Lituania 1
LU - Lussemburgo 1
LV - Lettonia 1
MX - Messico 1
PE - Perù 1
PT - Portogallo 1
SC - Seychelles 1
Totale 15.272
Salva come PNG Salva come JPEG
Città #
Fairfield 1.589
Woodbridge 1.361
Houston 993
Ann Arbor 893
Ashburn 736
Jacksonville 700
Wilmington 644
Seattle 634
Chandler 569
Cambridge 509
Dearborn 454
Singapore 376
Boardman 268
Princeton 211
Beijing 208
Dublin 198
Udine 146
San Diego 99
Izmir 78
Dong Ket 69
Ogden 51
Des Moines 44
Norwalk 43
Ottawa 39
Hefei 33
Kunming 26
Nanjing 26
Redmond 19
Trieste 19
Brussels 18
Guangzhou 18
Nanchang 15
Dallas 14
Hyderabad 13
Munich 13
New York 13
Simi Valley 13
Rome 12
Duino-Aurisina 11
Shenyang 11
Toronto 11
Chengdu 10
Council Bluffs 10
Leawood 10
Falls Church 9
Fuzhou 9
Redwood City 9
Shanghai 9
Venezia 9
Jinan 8
Lappeenranta 8
Lomé 8
Los Angeles 8
Santa Clara 8
Washington 8
Uppsala 7
Wuhan 7
Zhengzhou 7
Andover 6
Frankfurt am Main 6
Grafing 6
Helsinki 6
San Mateo 6
Chongqing 5
Hong Kong 5
Indiana 5
Milan 5
Phoenix 5
Shenzhen 5
Belgrade 4
Brno 4
Changsha 4
Fayetteville 4
Hebei 4
Moscow 4
Mumbai 4
Sacramento 4
Zanjan 4
Amsterdam 3
Augusta 3
Edinburgh 3
Fiumicino 3
Jiaxing 3
Lucca 3
Monmouth Junction 3
Ningbo 3
Olomouc 3
Pordenone 3
Tappahannock 3
Verona 3
Ardabil 2
Bologna 2
Buffalo 2
Cadoneghe 2
Cameri 2
Chicago 2
Clifton 2
Cossato 2
Eindhoven 2
Hangzhou 2
Totale 11.493
Salva come PNG Salva come JPEG
Nome #
Prognostic significance of the detection of tumour cells in peripheral blood stem cell collections in stage II and III breast cancer patients treated with high-dose therapy 236
Combined orthotopic heart transplantation followed by autologous stem cell transplantation in a patient with light chain amyloidosis and isolated cardiac involvement 166
The development of autoantibodies after allogeneic stem cell transplantation is related with chronic graft-vs-host disease and immune recovery 147
Minimal residual disease after transplantation or lenalidomide-based consolidation in myeloma patients: a prospective analysis 147
The role of positron emission tomography with 18F-fluorodeoxyglucose integrated with computed tomography in the evaluation of patients with multiple myeloma undergoing allogeneic stem cell transplantation 143
The genetic and genomic background of multiple myeloma patients achieving complete response after induction therapy with bortezomib, thalidomide and dexamethasone (VTD). 137
Predictive value of pretransplantation molecular minimal residual disease assessment by WT1 gene expression in FLT3-positive acute myeloid leukemia 137
Activity of all-trans-retinoic acid in a case of central nervous system extramedullary relapse of acute promyelocytic leukemia 134
Once-weekly carfilzomib, pomalidomide, and low-dose dexamethasone for relapsed/refractory myeloma: a phase I/II study 134
Bortezomib-melphalan-prednisone-thalidomide followed by maintenance with bortezomib-thalidomide compared with bortezomib-melphalan-prednisone for initial treatment of multiple myeloma: updated follow-up and improved survival. 133
Earlier administration of Rituximab allows higher rate of long-lasting response in adult patients with autoimmune thrombocytopenia 131
Allogeneic hematopoietic cell transplantation from unrelated donors in multiple myeloma: study from the Italian Bone Marrow Donor Registry. 127
Clinical feature and outcome in seven patients wuth hyaline or mixed variant of Castleman’s disease. A single centre experience 126
18F-FDG PET/CT focal, but not osteolytic, lesions predict the progression of smoldering myeloma to active disease 125
Rituximab therapy in adult patients with relapsed or refractory immune thrombocytopenic purpura: long-term follow-up results 123
Anti-CD20 therapy for chronic lymphocytic leukemia-associated autoimmune diseases 123
Allogeneic hematopoietic stem cell transplantation in myelofibrosis: the 20-year experience of the Gruppo Italiano Trapianto di Midollo Osseo (GITMO)” 122
Prognostic factors and outcome of Epstein-Barr virus DNAemia in high-risk recipients of allogeneic stem cell transplantation treated with preemptive rituximab. 122
B-cell immune reconstitution after allogenic stem cell transplantation and its role in the development of chronic graft-versus-host disease 121
Bortezomib-thalidomide-dexamethasone (VTD) is superior to bortezomib-cyclophosphamide-dexamethasone (VCD) as induction therapy prior to autologous stem cell transplantation in multiple myeloma. 121
Antilymphocyte Globulin for Prevention of Chronic Graft-versus-Host Disease 120
Long-Term Follow-Up of a Donor versus No-Donor Comparison in Patients with Multiple Myeloma in First Relapse after Failing Autologous Transplantation 119
Maintenance in myeloma patients achieving complete response after upfront therapy: a pooled analysis 118
Bortezomib-thalidomide-dexamethasone is superior to thalidomide-dexamethasone as consolidation therapy after autologous hematopoietic stem cell transplantation in patients with newly diagnosed multiple myeloma 114
Risk Factors and Outcomes of Infections by Multidrug-Resistant Gram-Negative Bacteria in Patients Undergoing Hematopoietic Stem Cell Transplantation 113
CD3+ graft cell count influence on chronic GVHD in haploidentical allogeneic transplantation using post-transplant cyclophosphamide 112
Allogeneic stem cell transplantation in multiple myeloma relapsed after autograft: A multicenter retrospective study based on donor availability 112
Image interpretation criteria for FDG PET/CT in multiple myeloma: a new proposal from an Italian expert panel. IMPeTUs (Italian Myeloma criteria for PET USe) 111
Allogeneic Stem Cell Transplantation for Relapsed/Refractory B Cell Lymphomas: Results of a Multicenter Phase II Prospective Trial including Rituximab in the Reduced-Intensity Conditioning Regimen. 111
Continuous therapy in standard- and high-risk newly-diagnosed multiple myeloma: A pooled analysis of 2 phase III trials 111
Brentuximab vedotin in patients with Hodgkin lymphoma and a failed allogeneic stem cell transplantation: results from a named patient program at four Italian centers. 110
Short-term thalidomide incorporated into double autologous stem-cell transplantation improves outcomes in comparison with double autotransplantation for multiple myeloma. 110
A comparison of allografting with autografting for newly diagnosed myeloma 108
Prospective molecular monitoring of minimal residual disease after non-myeloablative allografting in newly diagnosed multiple myeloma. 108
Continuous therapy versus fixed duration of therapy in patients with newly diagnosed multiple myeloma 108
Antimicrobial resistance in Gram-negative rods causing bacteremia in hematopoietic stem cell transplant patients: intercontinental prospective study of Infectious Diseases Working Party of the European Bone Marrow Transplantation group 107
Rituximab for the treatment of type II mixed cryoglobulinemia 106
Busulfan plus cyclophosphamide versus busulfan plus fludarabine as a preparative regimen for allogeneic haemopoietic stem-cell transplantation in patients with acute myeloid leukaemia: an open-label, multicentre, randomised, phase 3 trial. 105
Bendamustine in relapsed/refractory multiple myeloma: the "real-life" side of the moon. 104
Chemotherapy plus lenalidomide versus autologous transplantation, followed by lenalidomide plus prednisone versus lenalidomide maintenance, in patients with multiple myeloma: a randomised, multicentre, phase 3 trial. 104
New drugs and allogeneic hematopoietic stem cell transplantation for hematological malignancies: do they have a role in bridging, consolidating or conditioning transplantation treatment? 104
Defibrotide : review on clinical use and future development 103
Efficacy and safety of peripheral blood stem cell mobilization and collection: a single-center experience in 190 allogeneic donors. 102
Impact of hepatitis C virus infection on clinical features, quality of life and survival of patients with lymphoplasmacytoid lymphoma/immunocytoma 102
Flow cytometry evaluation of plasma cells contaminating leukapheresis pre- and post- CD34-positive selection- 100
JAK-2 inhibitors and allogeneic transplant in myelofibrosis 99
Lower dose rituximab is active in adults patients with idiopathic thrombocytopenic purpura 98
Intensified full-dose induction therapy (HD-MACHOP+radiotherapy) follwed dy consolidation with BAVC regimen and autologous stem cell transplantation as fron-line therapeutic approach for high risk aggressive non Hodgkin lymphoma 97
Factors affecting outcome of allogeneic stem cell transplantation as salvage in patients with acute myeloid leukemia primary refractory to intensive induction therapy. 97
Triplet vs doublet lenalidomide-containing regimens for the treatment of elderly patients with newly diagnosed multiple myeloma 97
Acute myeloid leukemia following chronic low-dose cyclophosphamide in metastatic breast cancer 96
Interpretation criteria for FDG PET/CT in multiple myeloma (IMPeTUs): final results. IMPeTUs (Italian myeloma criteria for PET USe) 95
Phase II trial to investigate efficacy and safety of bendamustine, dexamethasone and thalidomide in relapsed or refractory multiple myeloma patients after treatment with lenalidomide and bortezomib 95
T-cell chimerism and clinical outcome after reduced-intensity conditioning allogeneic stem cell transplantation 94
Cytokines dysregulation and chronic graft versus host disease after allogeneic haematopoieitc stem cell transplantation with reduced intensity conditioning 94
Autologous transplant vs oral chemotherapy and lenalidomide in newly diagnosed young myeloma patients: a pooled analysis 94
Busulfan- or Thiotepa-Based Conditioning in Myelofibrosis: A Phase II Multicenter Randomized Study from the GITMO Group 94
Acute hepatic failure as onset of progressive sclerodermatous chronic graft-versus-host disease after donor lymphocyte infusion. 93
Factors predicting outcome after allogeneic transplant in refractory acute myeloid leukemia: a retrospective analysis of Gruppo Italiano Trapianto di Midollo Osseo (GITMO) 92
‘Real-life’ report on the management of chronic GvHD in the gruppo Italiano trapianto midollo osseo (GITMO) 92
Extramedullary intracranial localization of multiple myeloma and treatment with novel agents: a retrospective survey in 50 patients 92
Multiple Myeloma: presenting features and survival according to hospital referral 90
Allogeneic transplantation improves the overall and progression-free survival of Hodgkin lymphoma patients relapsing after autologous: a retrospective study based on the time of HLA typing and donor availability 89
Consensus statement from European experts on the diagnosis, management, and treatment of multiple myeloma: from standard therapy to novel approaches. 89
Occurrence of multiple myeloma after fludarabine treatment of a chronic lymphocytic leukemia: evidence of a biclonal derivation and clinical response to autologous transplantation 88
Acute GVHD prophylaxis plus ATLG after myeloablative allogeneic haemopoietic peripheral blood stem-cell transplantation from HLA-identical siblings in patients with acute myeloid leukaemia in remission: final results of quality of life and long-term outcome analysis of a phase 3 randomised study 88
Lamivudine allows completion of chemotherapy in lymphoma patients with hepatitis B reactivation 87
Complete response correlates with long-term progression-free and overall survival in elderly myeloma treated with novel agents: analysis of 1175 patients 87
Prognostic significance of delayed thrombocytopenia after allogeneic stem cell transplant 87
FEASIBILITY AND OUTCOME OF ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION IN PATIENTS OLDER THAN 60 YEARS WITH POOR RISK ACUTE MYELOID LEUKEMIA 86
Treatment of refractory chronic GVHD with rituximab: a GITMO study 86
Improvement of amyloid-related symptoms after autologous stem cell transplantation in a patient with hepatomegaly, macroglossia and purpura 85
Sequential study of cytokine and lymphocyte patterns in patients with chronic agraft versus host disease after reduced intensity conditioning allogenic stem cell transplantation 84
Bortezomib as induction before autologous transplantation, followed by lenalidomide as consolidation-maintenance in untreated multiple myeloma patients. 84
B-cell depletion with rituximab as treatment for immune hemolytic anemia and chronic thrombocytopenia. 83
The hematopoietic cell transplantation comorbidity index (HCT-CI) predicts clinical outcomes in lymphoma and myeloma patients after reduced-intensity or non-myeloablative allogeneic stem cell transplantation 83
KERATOCONJUNCTIVITIS TREATMENT WITH AUTOLOGOUS SERUM EYE IN PATIENTS WITH SEVERE CHRONIC GVHD 82
Efficacy and safety of once-weekly bortezomib in multiple myeloma patients. 82
Successful mobilization of PBSCs predicts favorable outcomes in multiple myeloma patients treated with novel agents and autologous transplantation. 82
Allogeneic stem cell transplantation and novel therapies: is the treatment paradigm for younger patients with chronic lymphocytic leukemia changing? 82
Efficacy of tuemor necrosis factor alfa blockade with infliximab for the treatment of svere steroid-refractory acute graft versus host disease. 81
Pseudomonas pickettii (Biovar VA-II): a rare cause of bacteremias in haematologic patients. 80
Long-lasting complete remission of hepatitis C virus (HCV) infection and HCV-associated immunocytoma with alpha-interferon treatment 80
Long lasting remission after haploidentical stem cell transplant and pre-emptive donor lymphocyte infusions in a patient with primary refractory Hodgkin lymphoma 80
Autologous transplantation and maintenance therapy in multiple myeloma 80
Prospective, randomized study of single compared with double autologous stem-cell transplantation for multiple myeloma: Bologna 96 clinical study 79
Kinetics of Th1/Th2 cytokines and lymphocyte subsets to predict chronic GVHD after allo-SCT: results of a prospective study. 79
High dose therapy with stem cell rescue in elderly atients with aggressive poor risk lymphomas: a review of 14 cases. 78
Incidence, outcome, and risk factors of late-onset noninfectious pulmonary complications after unrelated donor stem cell transplantation 78
Considerations in the treatment of multiple myeloma: a consensus statement from Italian experts 78
Prognostic or predictive value of circulating cytokines and angiogenic factors for initial treatment of multiple myeloma in the GIMEMA MM0305 randomized controlled trial 78
Bortezomib plus dexamethasone followed by escalating donor lymphocyte infusions for patients with multiple myeloma relapsing or progressing after allogeneic stem cell transplantation 77
Non-myeloablative allografting for newly diagnosed multiple myeloma: the experience of the Gruppo Italiano Trapianti di Midollo 77
The genotype of the hepatitis C virus in patients with HCV-related B cell non-Hodgkin's lymphoma. 77
Impact of cytomegalovirus replication and cytomegalovirus serostatus on the outcome of patients with B cell lymphoma after allogeneic stem cell transplantation. 77
Incidence and outcome of invasive fungal diseases after allogeneic stem cell transplantation: a prospective study of the Gruppo Italiano Trapianto Midollo Osseo (GITMO). 77
The impact of histopathologic examination of graft-versus-host disease in the era of reduced-intensity conditioning regimen: a study from the Gruppo Italiano Trapianto di Midollo Osseo 77
Outcome of allogeneic stem cell transplantation following reduced-intensity conditioninig regimen in patients with idiopathic myelofibrosis: the G.I.T.M.O. Experience. 77
Qualitative and quantitative polymerase chain reaction monitoring minimal residual disease in relapsed chronic lymphocytic leukemia: early assessment can predict long-term outcome after reduced intensity allogeneic transplantation . 77
Allogeneic transplantation following a reduced-intensity conditioning regimen in relapsed/refractory peripheral T-cell lymphomas: long-term remissions and response to donor lymphocyte infusions support the role of a graft-versus-lymphoma effect. 76
Totale 10.183
Salva come PNG Salva come JPEG
Categoria #
all - tutte 58.649
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 58.649
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/20202.813 0 0 0 0 0 707 499 529 333 354 101 290
2020/20212.689 50 294 71 393 74 354 234 328 317 104 288 182
2021/20221.611 68 205 85 102 37 69 101 77 15 269 328 255
2022/20231.465 224 73 13 177 142 428 1 103 220 17 32 35
2023/2024489 64 28 10 17 67 53 25 43 81 46 26 29
2024/20251.052 86 285 121 89 295 176 0 0 0 0 0 0
Totale 15.873